et al., Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237 (Peer Reviewed) (not included in the study count)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxych loroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
HC Q is more potent than C Q in vitro for inhibiting SARS-CoV-2. Simulates HC Q concentration in lung fluid and provides dosing recommendations.
Please send us corrections, updates, or comments: